About chornixadm

This author has not yet filled in any details.
So far chornixadm has created 21 blog entries.

It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago

This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...

By | June 22nd, 2017|Chronix news|0 Comments

Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy1 compared to CA19-9, a commonly used biomarker.

By | June 14th, 2017|Chronix news|0 Comments

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO

Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).

By | June 5th, 2017|Chronix news|0 Comments

Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO. Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion.

By | June 5th, 2017|Peer-reviewed medical publications|0 Comments

Chronix Biomedical is pleased to be a sponsor of the PCRT annual meeting

Chronix Biomedical

Chronix looks forward to working with this team of international pancreatic cancer experts.

By | June 2nd, 2017|Chronix news|0 Comments

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

By | June 2nd, 2017|Chronix news|0 Comments

Invitation to visit Chronix booth at ASCO. Join us in #TheTurningPointInCancerFight

CNI MONITOR. Developed by doctors for doctors. The new tool for drug efficacy. VISIT US on Chronix Booth #5147 Chronix Biomedical has published recently its results of a blinded prospective clinical trial validating the use of the CNI MONITOR blood test to predict treatment outcome of patients undergoing therapy. Meet the experts involved with [...]

By | May 16th, 2017|Events|0 Comments

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

By | May 14th, 2017|Peer-reviewed medical publications|0 Comments

Cohort Study in LiverTx

Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286

Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.

By | May 11th, 2017|Peer-reviewed medical publications|0 Comments

Digital PCR of cfDNA for Transplant Rejetion

Beck J. et alDigital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 ;59:1732-41

Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA.

By | May 7th, 2017|Peer-reviewed medical publications|0 Comments